8-K filed April 20, 2026, 7:59 PM ET ticker IGC CIK 0001326205

debt confidence high sentiment neutral materiality 0.60

IGC Pharma raises $514K via two convertible promissory notes with OID

IGC Pharma, Inc.

FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.
Vanquish note: $238,050 principal at $207K purchase price, OID $31,050, 12% interest, matures March 30, 2027.
Upon default, holders can convert at 75% of lowest trading price over prior 10 days; 4.99% beneficial ownership cap per holder.
Conversion capped at 19.99% of outstanding shares without shareholder approval; proceeds for general working capital.
Notes are unregistered, issued as exempt under Section 4(a)(2) of the Securities Act.

item 1.01 item 2.03 item 3.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001185185-26-001437
form_type: 8-K
ticker: IGC
cik: 0001326205
company_name: IGC Pharma, Inc.
filed_at: 2026-04-20T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.136213+00:00
generated_at: 2026-05-15T05:17:26.226424+00:00
sec_items: ["1.01", "2.03", "3.02", "9.01"]
event_type: debt
sentiment: neutral
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001185185-26-001437
json_url: https://secwatch.observer/filing/0001185185-26-001437.json
markdown_url: https://secwatch.observer/filing/0001185185-26-001437.md
text_url: https://secwatch.observer/filing/0001185185-26-001437.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1326205/000118518526001437/0001185185-26-001437-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1326205/000118518526001437/igc8k200426.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

4f25dd6dfd9207988147cecac2c9f2e3bd6490ef

IGC Pharma, Inc. incurred convertible notes of $346,910 with FirstFire Global Opportunities Fund, LLC at 12% maturing April 10, 2027.

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

SEC 8-K Item 2.03/2.04 confidence 0.95 SEC evidence

d837a15c95801beaef42df38be0c6f80e4d6db17

IGC Pharma, Inc. incurred convertible notes of $238,050 with Vanquish Funding Group Inc. at 12% maturing March 30, 2027.

In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice. Solely upon the occurrence and continuation of an Event of Default under each of the Notes, each of VFG and FirstFire has the right, but not the obligation, to convert all or any portion of the outstanding balance of its respective Note — including principal, accrued interest, and any applicable default amounts — into shares (the “Conversion Shares”) of

SEC 8-K Item 2.03/2.04 confidence 0.95 SEC evidence

00775a5678e70cd06db44124ad73f08fa56e881a

IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with FirstFire Global Opportunities Fund, LLC valued at Aggregate principal amount of $346,910 (original issue discount of $39,910), purchase price $307,000 (effective 2026-04-14).

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

d165893763982c1a4cb4da11ca37a09a0d518c18

IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with Vanquish Funding Group Inc. valued at Aggregate principal amount of $238,050 (original issue discount of $31,050), purchase price $207,000 (effective 2026-04-14).

In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

Comparable filings

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

Filing page SEC filing

HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032

Healthcare Realty Trust Inc May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032

Filing page SEC filing

NWE

NorthWestern Energy subsidiary enters $225M secured term loan, repays revolver

NorthWestern Energy Group, Inc. June 2, 2026, 7:22 AM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

NW Corp's obligations under the Term Loan are secured by a $225 million first mortgage bond

Filing page SEC filing

TCPC

BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities

BlackRock TCP Capital Corp. June 1, 2026, 4:50 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

Filing page SEC filing

EHC

Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028

Encompass Health Corp June 1, 2026, 4:26 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.

Filing page SEC filing

VVX

V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin

V2X, Inc. June 1, 2026, 4:10 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.

Filing page SEC filing

AZZ

AZZ refinances revolver; maturity extended to 2029, margins cut 50 bps

AZZ INC May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

The Seventh Amendment (i) terminated the Initial Revolving Credit Commitments and simultaneously replaced them in their entirety with Extended Revolving Credit Commitments having a Maturity Date of May 7, 2029, (ii) decreased the interest rate margin applicable to the Revolving Credit Loans from margins ranging from 175 basis points to 275 basis points (subject to leverage ratio step-downs) to margins ranging from 125 basis points to 225 basis points (subject to leverage ratio step-downs)

Filing page SEC filing

ILPT

ILPT Mountain JV closes $1.62B loan at 5.71% fixed, repays $1.6B existing debt

Industrial Logistics Properties Trust May 8, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora

Comparable filing

Stanley Bank, N.A., Bank of America, N.A., Bank of Montreal and UBS AG New York Branch, or collectively, the lenders, pursuant to which Mountain JV obtained, in aggregate, a $1.62 billion loan secured by 90 of its properties, or the Loan . Also on May 8, 2026, we entered into a guaranty in favor of the lenders, pursuant to which we guaranteed certain limited

Filing page SEC filing

Source: SEC EDGAR

accession 0001185185-26-001437

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.